Literature DB >> 21562753

The association of diabetes mellitus and high-grade prostate cancer in a multiethnic biopsy series.

Daniel M Moreira1, Tiffany Anderson, Leah Gerber, Jean-Alfred Thomas, Lionel L Bañez, Madeline G McKeever, Cathrine Hoyo, Delores Grant, Jayakrishnan Jayachandran, Stephen J Freedland.   

Abstract

OBJECTIVE: To analyze the association of diabetes mellitus (DM) with risk of prostate cancer and cancer grade among men undergoing prostate biopsy and to analyze how obesity and race modify these associations.
MATERIALS AND METHODS: Retrospective analysis of 998 men from the Durham VA undergoing first prostate biopsy between 2001 and 2009 with complete data available. History of DM was determined by chart review. Patients' characteristics at biopsy were analyzed with chi-square and ranksum. Multivariable analyses of DM and risk of cancer and cancer grade were done using logistic regression adjusting for PSA, body mass index, race, age, year, and digital rectal exam.
RESULTS: At biopsy, 284 (28%) men had DM. DM was associated with African American (AAM; p = 0.010) and higher BMI (p < 0.001). DM was not associated with prostate cancer risk on either bivariate (p = 0.600) or multivariate analysis (p = 0.485). Similar results were found after stratification by race and obesity. In multivariable analysis, DM was associated with greater risk of high-grade disease (RR = 2.13, p = 0.024). The association was stronger among obese men (RR = 3.84, p = 0.020) and null in non-obese subjects (RR = 1.39, p = 0.460). After further stratification by race, DM was associated with high-grade disease only in obese Caucasian men (CM; RR = 5.81, p = 0.025) but not in obese AAM. DM was not associated with risk of low-grade disease in all men together or after stratification by obesity or race.
CONCLUSION: History of DM was associated with greater risk of high-grade disease. The association was strongest among obese CM suggesting the effect of DM on high-grade prostate cancer is modified by race and obesity.

Entities:  

Mesh:

Year:  2011        PMID: 21562753     DOI: 10.1007/s10552-011-9770-3

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  18 in total

1.  Prostate cancer risk in pre-diabetic men: a matched cohort study.

Authors:  Adedayo A Onitilo; Richard L Berg; Jessica M Engel; Rachel V Stankowski; Ingrid Glurich; Gail M Williams; Suhail A R Doi
Journal:  Clin Med Res       Date:  2013-05-08

2.  Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.

Authors:  Melissa A Babcook; Sanjeev Shukla; Pingfu Fu; Edwin J Vazquez; Michelle A Puchowicz; Joseph P Molter; Christine Z Oak; Gregory T MacLennan; Chris A Flask; Daniel J Lindner; Yvonne Parker; Firouz Daneshgari; Sanjay Gupta
Journal:  Mol Cancer Ther       Date:  2014-08-13       Impact factor: 6.261

Review 3.  Risk-based prostate cancer screening.

Authors:  Xiaoye Zhu; Peter C Albertsen; Gerald L Andriole; Monique J Roobol; Fritz H Schröder; Andrew J Vickers
Journal:  Eur Urol       Date:  2011-11-24       Impact factor: 20.096

4.  The association between overall survival of prostate cancer patients and hypertension, hyperglycemia, and overweight in Southern China: a prospective cohort study.

Authors:  Hua Xu; Li-min Zhang; Jun Liu; Guan-xiong Ding; Qiang Ding; Hao-wen Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2013-02-27       Impact factor: 4.553

5.  The association between race and prostate cancer risk on initial biopsy in an equal access, multiethnic cohort.

Authors:  Alexis R Gaines; Elizabeth L Turner; Patricia G Moorman; Stephen J Freedland; Christopher J Keto; Megan E McPhail; Delores J Grant; Adriana C Vidal; Cathrine Hoyo
Journal:  Cancer Causes Control       Date:  2014-05-31       Impact factor: 2.506

6.  Concurrent Diabetes Mellitus may Negatively Influence Clinical Progression and Response to Androgen Deprivation Therapy in Patients with Advanced Prostate Cancer.

Authors:  Jeffrey Shevach; Emily Jane Gallagher; Teena Kochukoshy; Victoria Gresia; Manpreet Brar; Matthew D Galsky; William K Oh
Journal:  Front Oncol       Date:  2015-06-15       Impact factor: 6.244

7.  Obesity, diabetes and aggressive prostate cancer hormone-naïve at initial diagnosis.

Authors:  Simona Di Francesco; Raffaele L Tenaglia
Journal:  Cent European J Urol       Date:  2014-01-27

8.  Diabetes and Prostate Cancer Outcomes in Obese and Nonobese Men After Radical Prostatectomy.

Authors:  Sonia Kelkar; Taofik Oyekunle; Adva Eisenberg; Lauren Howard; William J Aronson; Christopher J Kane; Christopher L Amling; Matthew R Cooperberg; Zachary Klaassen; Martha K Terris; Stephen J Freedland; Ilona Csizmadi
Journal:  JNCI Cancer Spectr       Date:  2021-03-09

9.  Prostate cancer in patients with metabolic syndrome is associated with low grade Gleason score when diagnosed on biopsy.

Authors:  Kyoung Pil Jeon; Tae Yoong Jeong; Seo Yeon Lee; Sang Won Hwang; Joong Hui Shin; Dong Suk Kim
Journal:  Korean J Urol       Date:  2012-09-19

Review 10.  Prostate carcinogenesis with diabetes and androgen-deprivation-therapy-related diabetes: an update.

Authors:  Noboru Hara
Journal:  Exp Diabetes Res       Date:  2012-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.